Dasatinib | Buy Online | Senolytic Research Guide

A 72-year-old woman with idiopathic pulmonary fibrosis — a disease where the lungs progressively stiffen and suffocate — enrolled in a small clinical trial at Mayo Clinic in 2019. She was given a drug combination that had never been tested in humans for this purpose: dasatinib plus quercetin, administered in brief intermittent pulses rather than daily doses. After three weeks, her six-minute walk distance improved by 22 meters. Her physical function scores climbed. Lung function stabilized.

The researchers weren't treating her cancer. They were targeting senescent cells — the so-called "zombie cells" that accumulate in aging tissue, refuse to die, and poison surrounding cells with a toxic inflammatory cocktail. Dasatinib, a drug originally approved to treat leukemia, turned out to be one of the most potent tools ever discovered for hunting these cells down.

That trial — the first human senolytic study in history — changed the trajectory of aging research. And dasatinib sits at the center of it.

---

The Discovery: From Cancer Ward to Longevity Lab

Dasatinib's story begins not in a longevity clinic but in the oncology wards of the early 2000s. Bristol-Myers Squibb chemists were working on next-generation tyrosine kinase inhibitors to overcome resistance to imatinib (Gleevec), the first-in-class BCR-ABL inhibitor that had revolutionized treatment of chronic myeloid leukemia (CML). Some CML patients developed mutations in the BCR-ABL kinase domain that made imatinib useless. The solution was a more promiscuous inhibitor — one that hit a broader range of kinase conformations.

Dasatinib, synthesized in 2003 and FDA-approved in 2006 under the brand name Sprycel, fit the bill. It inhibited BCR-ABL with roughly 325-fold greater potency than imatinib and simultaneously blocked the SRC family kinases — a group of non-receptor tyrosine kinases involved in cell proliferation, adhesion, and survival signaling. For oncologists, this dual action was valuable because it suppressed multiple resistance mechanisms at once.

For a decade, dasatinib's story was purely one of cancer medicine. Then, in 2015, a paper landed in the journal *Cell* that reframed everything.

Judith Campisi at the Buck Institute for Research on Aging and Jan van Deursen at Mayo Clinic had been unraveling the biology of cellular senescence — the state where cells stop dividing but refuse to undergo apoptosis (programmed cell death). These cells accumulate with age and disease, secreting a toxic mixture of pro-inflammatory cytokines, proteases, and growth factors collectively called the senescence-associated secretory phenotype (SASP). In mouse models, clearing senescent cells improved multiple aging phenotypes simultaneously.

The Mayo team — led by James Kirkland and Tamara Tchkonia — asked a simple but radical question: could existing drugs selectively kill senescent cells? They screened dozens of compounds against senescent versus non-senescent human preadipocytes and endothelial cells. Dasatinib emerged as one of the top hits, particularly potent against senescent fat progenitor cells. Quercetin, a plant flavonoid, was potent in other cell types. Together, the D+Q combination became the defining senolytic protocol.

The 2015 *Cell* paper reported that a single dose of D+Q in aged mice extended median lifespan, improved physical function, and reduced multiple markers of frailty. The aging research community — a field used to incremental progress — took notice immediately.

---

Chemical Identity: Structure and Properties

Dasatinib's chemical name is N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide monohydrate. That's a mouthful. The key structural features are:

Structurally, dasatinib is a thiazolecarboxamide derivative. Its unique dual-binding geometry lets it engage the ABL kinase in both its active and inactive conformations — a flexibility that most first-generation kinase inhibitors lacked. The piperazine side chain improves bioavailability and plasma protein binding. The chloro-methylphenyl group anchors the molecule into the ATP-binding pocket of target kinases.

For researchers, the poor aqueous solubility is the practical challenge. Dasatinib is typically dissolved in a small volume of DMSO (5–10% of final volume) and then diluted with acidified water or a suitable vehicle. In the clinical setting, oral formulations handle this with enteric-coated tablets. Research-grade material requires careful reconstitution — more on that in the dosing section.

Bioavailability after oral administration is approximately 14–34% in clinical data, with significant food effects: a high-fat meal increases AUC by roughly 14%. Plasma half-life is 3–5 hours, which sounds short, but the pharmacodynamic effects on target kinases persist considerably longer than plasma levels suggest — a key point for designing intermittent senolytic protocols.

---

Mechanism of Action: How Dasatinib Kills Zombie Cells

Primary Mechanism: Targeting Senescent Cell Survival Pathways

Senescent cells aren't just dysfunctional — they're actively fighting to stay alive. Normal cells that sustain DNA damage or reach their replicative limit would typically undergo apoptosis. Senescent cells, however, upregulate an array of anti-apoptotic survival networks that keep them alive despite severe cellular damage. This is the core vulnerability that senolytics exploit.

Dasatinib's primary senolytic mechanism centers on inhibiting SRC family kinases (SFKs) — particularly SRC, LYN, YES, and FYN — along with BCR-ABL, ephrin receptors (EPH), and discoidin domain receptors (DDR). These kinases feed into two major survival cascades that are hyperactivated in senescent cells:

1. PI3K/AKT/mTOR pathway: SRC kinases phosphorylate and activate PI3K, which activates AKT, which in turn activates mTOR and phosphorylates the pro-apoptotic protein BAD, sequestering it and preventing its death-inducing activity. Dasatinib disrupts this chain at the SRC level, allowing BAD to be released and activate caspase cascades.

2. BCL-2/BCL-xL anti-apoptotic network: Senescent cells massively upregulate BCL-2 family anti-apoptotic proteins. While dasatinib doesn't directly inhibit BCL-2, it reduces upstream survival signaling that maintains BCL-2 expression, effectively lowering the apoptotic threshold in senescent cells.

The crucial selectivity question — why does dasatinib kill senescent cells but not normal cells — comes down to differential dependency. Normal cells use SRC signaling but aren't existentially dependent on it for survival. Senescent cells, having shut down normal proliferative and metabolic programs, become hyperdependent on SRC-mediated survival pathways. Remove those pathways, and the senescent cell — already teetering on the edge of apoptosis — tips over.

In a 2015 *Cell* study, dasatinib eliminated >50% of senescent human preadipocytes within 72 hours at concentrations of 100–250 nM, while having minimal effect on proliferating or quiescent non-senescent cells at the same concentrations.

Secondary Pathways: Inflammation, Fibrosis, and Metabolism

Beyond direct senolytic killing, dasatinib has secondary mechanisms relevant to aging biology:

SASP suppression: Even before senescent cells die, dasatinib treatment reduces SASP output. SRC kinases are upstream activators of NF-κB — the master transcription factor driving SASP cytokine production. Dasatinib-mediated SRC inhibition reduces NF-κB nuclear translocation, decreasing secretion of IL-6, IL-8, MCP-1, MMP-3, and other SASP factors within hours of treatment.

Ephrin receptor inhibition: Dasatinib potently inhibits EPHA2 and EPHB4 receptors. These receptors regulate cell-cell repulsion and tissue boundary maintenance. In the context of senescence, ephrin signaling helps senescent cells resist elimination by neighboring immune cells. Blocking ephrin receptors may improve immune clearance of senescent cells — the natural mechanism that normally removes them but fails with age.

DDR1/DDR2 inhibition: Discoidin domain receptors are collagen-binding receptor tyrosine kinases. Their inhibition by dasatinib is particularly relevant to fibrotic diseases where senescent cells drive collagen deposition. This mechanism likely explains dasatinib's pronounced efficacy in the pulmonary fibrosis trials.

Adipose tissue effects: Dasatinib is exceptionally potent in senescent preadipocytes — fat cell precursors that accumulate in aging adipose tissue and contribute to metabolic dysfunction, inflammation, and the physical frailty phenotype. This selectivity for fat-derived senescent cells is one reason the D+Q combination is so effective in metabolic aging studies.

Systemic vs. Local Effects: Administration Route Matters

Oral administration produces systemic distribution — dasatinib reaches virtually all tissues with reasonable vascularity. This is appropriate for targeting senescent cells in multiple organ systems simultaneously, which is the goal of most longevity protocols.

CNS penetration is limited but not zero. Dasatinib crosses the blood-brain barrier at low levels — approximately 0.5–1% of plasma concentration in animal models. This may be sufficient for some CNS senolytic effects, though brain-focused protocols may require optimization. The Mayo group has begun exploring CNS-specific senolytic applications, including in Alzheimer's disease models.

Intravenous or intraperitoneal administration in animal models produces faster peak concentrations and is used in most preclinical studies, but clinical and research applications typically use oral routes for practical reasons.

---

The Evidence Base: What Research Actually Shows

Cellular Senescence Clearance

Zhu et al., 2015 (Cell) — The landmark paper. Human preadipocytes and endothelial cells were treated with dasatinib (0–500 nM), quercetin (0–50 μM), or both. Dasatinib eliminated senescent preadipocytes with an EC50 of ~100 nM and reduced SASP markers by 30–50%. The combination was more effective than either agent alone across multiple cell types. In aged mice, a single oral dose course (5 mg/kg dasatinib + 50 mg/kg quercetin × 3 doses) improved physical function metrics and grip strength within two weeks, effects that lasted for months after drug clearance — consistent with senescent cell elimination rather than acute drug effects.

Xu et al., 2018 (Nature Medicine) — Transplanting senescent cells into young mice caused persistent physical dysfunction and decreased survival. D+Q treatment reversed these effects. The study also showed that naturally aged mice treated with D+Q had improved grip strength, exercise capacity, and gait speed compared to vehicle-treated controls. Critically, the treated mice showed >25% improvement in median remaining lifespan when treatment began at 24 months of age.

Kirkland et al., 2017 (JCI Insight) — Characterized the senolytic activity of D+Q in multiple human cell types including preadipocytes, endothelial cells, and lung epithelial cells. Dasatinib showed the strongest effect in fat-derived cells; quercetin was most potent in endothelial and lung cells. This complementary cell-type specificity is the mechanistic rationale for combining the two agents.

Pulmonary Fibrosis

Schafer et al., 2017 (Nature Communications) — Bleomycin-induced lung fibrosis in mice was treated with D+Q starting 2 weeks after injury. Treated mice showed significantly reduced lung senescence burden, decreased collagen deposition, and improved lung compliance compared to controls. The researchers identified senescent alveolar epithelial cells as key drivers of fibrosis progression — and dasatinib's DDR1/DDR2 inhibition as a likely mechanism beyond direct senolytic effects.

Justice et al., 2019 (EBioMedicine) — The first human senolytic clinical trial. Fourteen patients with idiopathic pulmonary fibrosis received D+Q (dasatinib 100 mg + quercetin 1000 mg) for 3 days, then off for 18 days, repeated for 3 cycles. Primary endpoints were safety and feasibility — and the drug combination was tolerated without serious adverse events. Secondary signals: 6-minute walk distance improved by 22.3 meters, physical function scores improved, and circulating senescent cell markers decreased. The study was small and uncontrolled, but the directional findings were striking for a disease with essentially no effective treatments.

Physical Function and Frailty

Xu et al., 2021 (Nature Aging) — Aged mice (20 months) treated intermittently with D+Q showed improvements in grip strength (+20%), 4-limb hanging time (+30%), and gait speed compared to vehicle. The treated animals also had reduced adipose tissue inflammation, lower circulating IL-6 and TNF-α, and improved insulin sensitivity. Muscle histology showed preservation of type II (fast-twitch) fiber cross-sectional area — the fiber type most vulnerable to sarcopenia.

Hickson et al., 2019 (JCI Insight) — Nine patients with diabetic kidney disease received D+Q for 3 days. Adipose tissue and skin biopsies showed reduced senescent cell burden (p16^INK4a and p21^CIP1 expression) at 11 days post-treatment. Circulating SASP factors including IL-1α, IL-6, and MMP-2 decreased. This was the first demonstration that oral D+Q reduces senescent cell burden in human tissues — not just in culture or mice.

Cardiovascular and Metabolic Applications

Lewis-McDougall et al., 2019 (Aging Cell) — Aged mouse hearts showed accumulation of senescent cardiomyocytes and cardiac fibroblasts associated with diastolic dysfunction. D+Q treatment reduced cardiac senescence burden and improved diastolic filling parameters on echocardiography. Left ventricular compliance improved, and SASP-driven cardiac fibrosis was attenuated.

Palmer et al., 2019 (Diabetes) — In a mouse model of type 1 diabetes, transplanted senescent cells worsened insulin resistance and β-cell function. D+Q treatment reversed these metabolic effects. Notably, senescent β-cells themselves were cleared, suggesting potential applications in diabetes-associated pancreatic aging.

Ogrodnik et al., 2019 (Cell Reports) — Focused specifically on liver senescence and non-alcoholic fatty liver disease (NAFLD). Senescent hepatocytes and hepatic stellate cells drove steatosis and fibrosis in aged mice. D+Q treatment reduced hepatic senescence markers, decreased liver fat accumulation, and improved liver enzyme profiles. ALT and AST normalized by 30–40% in treated animals versus controls.

Research Summary Table

---

Complete Dosing Guide

Dasatinib is not a peptide in the traditional sense — it's a small molecule drug — but it's classified here within the senolytic research context where it's frequently studied alongside peptide-based anti-aging compounds. For research purposes, the following protocols reflect published clinical and preclinical data.

Critical note: Dasatinib is an FDA-approved prescription drug (Sprycel) used at much higher daily doses (70–140 mg/day) for CML treatment. The senolytic protocols use dramatically lower doses in intermittent pulses — a fundamentally different paradigm from oncology dosing. Research use should be approached with corresponding caution and ideally under medical supervision.

Reconstitution and Storage

For research solutions:

Stability: Dry powder is stable at room temperature for 2+ years if kept dry and sealed. DMSO stocks at -80°C are stable indefinitely.

Beginner Protocol (Conservative Research Starting Point)

For researchers new to senolytics, the most conservative approach mirrors the lowest doses showing effects in human trials:

Rationale: The 2-day-on, 28-day-off intermittent approach reflects the biology — senolytic killing occurs within 24–72 hours of drug exposure, and chronic dosing adds toxicity risk without adding senolytic benefit. Senescent cells don't regenerate rapidly; once cleared, the benefit persists for weeks to months.

Standard Protocol (Replicating Human Trial Parameters)

This mirrors the Justice et al. (2019) IPF trial design — the most clinically validated senolytic protocol to date:

Total dasatinib exposure per cycle: 300 mg over 3 days. This is roughly 1/14th the cumulative monthly dose used in CML treatment — a dramatically lower burden.

Advanced Protocol (Quarterly Maintenance)

For ongoing senolytic maintenance after an initial clearing cycle:

Navitoclax note: Some advanced protocols combine dasatinib with navitoclax (a BCL-2/BCL-xL inhibitor) for broader senolytic coverage. This combination shows superior senescent cell clearance in preclinical models but carries significant platelet toxicity risk (thrombocytopenia) and is strictly a research-only consideration.

---

Stacking Strategies

Stack 1: The Classic D+Q Protocol

The dasatinib + quercetin combination is the most validated senolytic stack in existence — it's what every human trial to date has used. The rationale is cell-type complementarity: dasatinib preferentially kills senescent preadipocytes and mesenchymal cells (SRC-dependent); quercetin preferentially kills senescent endothelial cells and lung epithelial cells (PI3K/AKT-dependent via different upstream pathways). Together they cover a much broader spectrum of senescent cell types than either alone.

Stack 2: D+Q + Fisetin (Broad-Spectrum Senolytic)

Fisetin — actually a flavonoid, not a peptide — provides additional coverage against senescent brain cells and T cells that D+Q misses. The Mayo group has published separately on fisetin's senolytic activity in brain tissue and immune senescence. Combining all three creates the broadest-spectrum senolytic protocol currently documented in research.

Stack 3: D+Q + Longevity Peptide Support

Senolytic clearing works best when paired with tissue regeneration support. Removing senescent cells creates space for stem cell repopulation and tissue repair — but aging stem cells need support to respond. This stack combines dasatinib-led senolysis with peptide compounds that support the regenerative response:

The timing sequence is deliberate: senolysis first (Days 1–3), then regenerative support (Days 10+) to fill the cleared cellular space. This mirrors how the body's natural senescence clearance-regeneration cycle is supposed to work in young tissue.

---

Safety Deep Dive

Dasatinib's safety profile is well-characterized from its oncology use — but the senolytic dosing context is fundamentally different. At 70–140 mg/day for months or years (CML dosing), dasatinib causes significant adverse effects. At 100 mg for 2–3 days per month (senolytic dosing), the risk profile is dramatically more favorable.

Common Side Effects at Senolytic Doses

Based on the published human senolytic trials (Justice et al. 2019; Hickson et al. 2019):

The short dosing window (2–3 days) is the key safety advantage. Most oncology-associated toxicities — pleural effusion, severe cytopenias, pulmonary hypertension — are cumulative effects of chronic dosing that simply don't apply to intermittent senolytic protocols.

Rare and Theoretical Risks

QT interval prolongation: Dasatinib can prolong the cardiac QT interval, increasing arrhythmia risk. At oncology doses this is clinically significant. At senolytic doses the risk is substantially lower but not zero. Baseline ECG is advisable, especially in patients with existing cardiac conditions or those taking other QT-prolonging agents.

Pleural effusion: The most common serious side effect in CML treatment (~20–35% incidence with chronic dosing) — fluid accumulation around the lungs. At intermittent senolytic doses, this risk appears very low based on published trials, but individuals with pre-existing pleural or cardiac disease should be monitored.

Thrombocytopenia: Platelet counts can drop with dasatinib. This is dose- and duration-dependent. Baseline platelet count >150,000/μL is advisable before starting. Avoid concurrent use of anticoagulants or high-dose aspirin during the dosing window.

Hepatotoxicity: Transient liver enzyme elevations are possible. Baseline LFTs and recheck at 2–4 weeks post-cycle. Patients with existing liver disease should approach with additional caution.

Drug interactions: Dasatinib is metabolized primarily by CYP3A4. Strong CYP3A4 inhibitors (ketoconazole, grapefruit juice, clarithromycin) can increase dasatinib levels significantly. Strong CYP3A4 inducers (rifampin, St. John's Wort, carbamazepine) decrease levels. Proton pump inhibitors reduce absorption by raising gastric pH — take 2 hours apart if concurrent use is unavoidable.

Contraindications

---

Dasatinib Compared to Alternatives

The senolytic field has grown rapidly since 2015. Dasatinib is no longer the only game in town. Here's how it compares to the main alternatives:

FOXO4-DRI is the peptide-based senolytic most directly comparable to dasatinib. Where dasatinib works through kinase inhibition to lower the apoptotic threshold, FOXO4-DRI works by disrupting the FOXO4-p53 interaction that keeps p53 trapped in the mitochondria of senescent cells — releasing p53 to trigger apoptosis. The mechanisms are complementary rather than redundant, which is why some advanced protocols combine both.

Navitoclax (ABT-263) is arguably more potent than dasatinib for raw senolytic activity, but its dose-limiting thrombocytopenia makes human use risky. Researchers have developed navitoclax prodrugs and locally-delivered formulations to get around this — an active area of development.

The practical conclusion: for human research protocols, D+Q remains the gold standard — the only combination with completed phase I human trials showing both safety and biological activity.

---

What's Coming Next: The Frontier of Dasatinib Research

The senolytic field is moving fast, and dasatinib is at the center of several ongoing investigations that could redefine how we think about aging medicine.

The SToMP-AD Trial: The Mayo Clinic launched a clinical trial (NCT04685590) testing D+Q in Alzheimer's disease patients. The hypothesis is that senescent cells in the brain — particularly senescent astrocytes and microglia — drive neuroinflammation and amyloid pathology. Early mouse data showed that D+Q reduced tau pathology and neuroinflammatory markers. Results from this human trial are among the most anticipated in aging medicine.

AFFIRM-NASH Trial: Testing D+Q in non-alcoholic steatohepatitis (NASH) — a disease with enormous unmet need and a clear senescence component. The liver accumulates senescent hepatic stellate cells and cholangiocytes that drive fibrosis. This trial could open an entirely new indication.

Osteoporosis: Senescent osteocytes and osteoblasts impair bone remodeling and contribute to age-related bone loss. A Mayo trial (NCT03675724) is evaluating D+Q in postmenopausal osteoporosis. Preliminary data suggests improvements in bone formation markers.

Senoblockers vs. Senolytics: An emerging debate in the field asks whether it's better to kill senescent cells (senolytics like dasatinib) or prevent cells from entering senescence in the first place (senostatics/senoblockers like rapamycin). The answer is probably both — different tools for different contexts. Understanding when to clear versus when to prevent will be a defining question for the next decade.

Targeted senolytic delivery: Current oral D+Q protocols distribute drug throughout the body, which is mostly beneficial but creates off-target effects. Researchers are developing nanoparticle delivery systems that target senescent cells specifically — using senescent-cell surface markers like galactosidase activity to trigger drug release selectively at senescent cells. This could dramatically improve the therapeutic window.

Biomarker development: One of the biggest unresolved problems is measuring the senolytic response. How do you know if a treatment actually cleared senescent cells in a specific tissue? Current approaches use circulating SASP markers (IL-6, IL-8, MMP-2), p16^INK4a expression in blood cells, and cell-free DNA methylation signatures. None are fully validated. Developing robust senolytic response biomarkers is essential for optimizing protocols and personalizing treatment.

Senescent cell heterogeneity: Not all senescent cells are equal. Replicative senescence, stress-induced premature senescence, and oncogene-induced senescence produce cells with different SASP profiles and different dependencies on survival pathways. Dasatinib may be highly effective against some senescent cell subtypes and less effective against others. Mapping this heterogeneity and matching senolytics to senescent cell types is a major ongoing research direction.

Combination with GLP-1 agonists: There's emerging evidence that metabolic improvement from GLP-1 receptor agonists like Semaglutide and Tirzepatide reduces the rate of senescent cell accumulation in adipose tissue. Combining metabolic optimization with periodic senolytic clearing may be more effective than either approach alone — a hypothesis being explored in several investigator-initiated trials.

---

Key Takeaways

---

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.

🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.

🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.

📚 Want more guides? — Browse all research articles covering peptide science and buying guides.

---

Related Articles on BuyPeptidesOnline.com